摘要
20世纪90年代之前,腹膜恶性肿瘤被认为是癌广泛转移的表现,缺乏理想治疗方法。之后,基于临床研究,国际肿瘤学界对此观念发生转变,认为部分经选择的病例,接受以肿瘤细胞减灭术(cytoreductive surgery,CRS)加腹腔热灌注化疗(hyperthermic intraperitoneal chemotherapy,HIPEC)为核心的综合治疗不但能够有效控制疾病进展,还有可能达到临床治愈。英国贝辛斯托克医院是最早开展腹膜肿瘤诊治和研究的中心之一,30余年来,在腹膜肿瘤的诊疗和国际腹膜表面恶性肿瘤学会(peritoneal surface oncology group international,PSOGI)的创立发展等领域均作出了历史性的贡献:1994年,贝辛斯托克医院在Paul H. Sugarbaker教授指导下开展了第1例CRS,目前每年完成CRS超过350例;1998年,贝辛斯托克医院主持召开了第1届PSOGI大会;建立多学科团队,发展和推广CRS+HIPEC治疗策略;制订腹膜假黏液瘤(pseudomyxoma peritonei,PMP)和恶性腹膜间皮瘤(malignant peritoneal mesothelioma,MPM)指南;开展联合CRS和多脏器移植治疗腹膜肿瘤等临床研究。贝辛斯托克是PSOGI的基础,也是PSOGI发展和延续的重要组成部分,并将取得更大进展和更为丰硕的研究成果。
Prior to the 1990’s peritoneal malignancy was categorized as “carcinomatosis” with a general acceptance that nothing could be done for those unfortunate enough to have malignant involvement of the peritoneum. Since then, based on clinical research,the international oncology community believed that some selected cases who underwent comprehensive treatment centered on cytoreductive surgery(CRS) and hyperthermic intraperitoneal chemotherapy(HIPEC) can not only acquire effective control of the disease, but also obtain clinical cure. Basingstoke and North Hampshire Hospital is one of the first centers to carry out basis and clinical research on peritoneal malignancy. Over the past 30 years, it has made historic contributions in the field of peritoneal malignancy and promoting the development of international collaborations. In March 1994, Basingstoke performed the first CRS under the guidance of Paul Sugarbaker and currently deliver >350 cases a year. In 1998, Basingstoke hospital organized the inaugural meeting of what is now Peritoneal Surface Oncology Group International(PSOGI). Basingstoke hospital has established a multidisciplinary team to develop and promote CRS + HIPEC treatment strategy, formulated pseudomyxoma peritonei(PMP) and malignant peritoneal mesothelioma(MPM) guidelines, and carried out clinical trials such as combined CRS and small bowel/modified multivisceral transplantation in the treatment of peritoneal malignancy. Basingstoke is proud to have been part of the foundation, development, and continuity of PSOGI and continues to do so.
作者
Brendan John Moran
安松林(翻译)
李雁(审校)
Brendan John Moran(Department of Peritoneal Malignancies,Basingstoke and North Hampshire Hospital,Hampshire RG249NA,UK)
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2022年第24期1284-1287,共4页
Chinese Journal of Clinical Oncology
关键词
腹膜恶性肿瘤
腹膜假黏液瘤
肿瘤细胞减灭术
腹腔热灌注化疗
peritoneal malignancy
pseudomyxoma peritonei(PMP)
cytoreductive surgery(CRS)
hyperthermic intraperitoneal chemotherapy(HIPEC)
